Itron SVP John Marcolini sells $946,085 in company shares

Itron insider John F. Marcolini sold 11,400 shares for $946,085 at $82.99 per share under a Rule 10(b)5-1 plan, leaving him with 13,289 shares. The article also notes Itron’s Q1 2026 beat, with EPS of $1.49 versus $1.23 expected and revenue of $587 million versus $572.09 million, though the stock remains down 31% over the past year near its 52-week low of $77.77. Roth/MKM cut its price target to $136 from $150 while keeping a Buy rating.

Analysis

The market is likely over-anchoring on the insider sale as a signal, but the more important takeaway is that the stock is already pricing in a meaningful reset in growth expectations while still implying modest execution risk rather than a structural impairment. When a company trades near cyclical lows after a strong quarter, the setup often shifts from earnings quality to whether the next 2-3 quarters can merely confirm stabilization; that is where multiples usually re-rate fastest. If management can keep revenue and backlog cadence intact, the downside from here is more likely limited to range-trading than a fresh derating.

The second-order issue is that complex-project businesses tend to create lumpy optics: one or two delayed deployments can make a fundamentally healthy demand environment look weak for several months. That matters because the sell-side tends to cut targets on near-term growth deceleration before the actual earnings power deteriorates, which creates a window where valuation compresses faster than fundamentals. For competitors, any softness in ITRI’s delivery cadence can temporarily benefit adjacent industrial software/meters vendors with cleaner revenue recognition and faster conversion of utility capex into reported growth.

The contrarian view is that the insider sale is less bearish than it appears because it was pre-programmed, but it may still cap enthusiasm among momentum buyers who were hoping for a quick mean reversion. The real catalyst sequence is not the next print itself, but whether management can translate beat-and-raise quality into improved guidance credibility over the next 1-2 earnings cycles. If that does not happen, the stock can stay cheap for months despite appearing undervalued on simple multiples.

From a risk perspective, the main tail risk is that the current valuation floor is an illusion if regulatory timing or project slippage pushes revenue out by another two quarters; in that case, multiple support can fail quickly because low-P/E industrials are often de-rated on estimate revisions, not absolute earnings. On the upside, any evidence of accelerating book-to-bill or margin expansion would likely trigger a sharp rerating because the stock has already been punished enough that incremental good news can have an outsized effect.

Key Decisions for Investors

• Initiate a tactical long in ITRI on weakness in the $78-$82 range with a 6-12 week horizon; risk/reward favors a move back toward prior support if the market stops treating project timing noise as structural damage.
• Buy ITRI call spreads 1-2 quarters out to express a rebound in confidence without paying full delta; target a scenario where guidance stabilization drives a quick re-rating, while capping downside to premium paid.
• If already long ITRI, hedge event risk into the next earnings update by trimming 25-33% of exposure and using puts below the 52-week low as insurance against another guidance reset.
• Relative-value idea: long ITRI / short a higher-multiple utility-tech or industrial automation peer with cleaner near-term execution, to isolate valuation mean reversion from broad-capex beta over the next 1-3 months.
• Avoid chasing the name until management commentary confirms backlog conversion; if estimate revisions continue lower over the next 30-45 days, wait for a second leg down before adding capital.